Phase 3 Krascendo 1 results suggest investigational divarasib could improve survival compared with currently approved KRAS G12C inhibitors in previously treated NSCLC.
|Videos|November 4, 2021
Assessing Octreotide Use in the Treatment of Carcinoid Crises in Patients With Neuroendocrine Tumors
Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, discusses what octreotide is and how it is used to reduce carcinoid crisis rates or treat a crisis.
Advertisement
Pharmacy Times interviewed Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, on his presentation at the 2021 NANETS Multidisciplinary NET Medical Virtual Symposium discussing a prospective study of carcinoid crisis with no perioperative octreotide.
During the interview, Pommier explained what octreotide is and how it is used to reduce carcinoid crisis rates or treat a crisis.
Advertisement
Related to this article
Nationwide Danish data presented at EASD 2026 link a widening cancer gap in type 2 diabetes largely to obesity-related cancers.
A randomized clinical trial found that dedicated oncology pharmacist care reduced adverse drug reactions among patients with hematologic malignancies.
Tucatinib’s new HER2-positive breast cancer maintenance indication extends disease control while requiring close liver monitoring and pharmacist coordination of oral therapy with ongoing antibody treatment.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
The PD-1 inhibitor is the first immunotherapy approved for stage II and III MSI-H/dMMR locally advanced rectal cancer and may allow eligible patients to avoid chemotherapy, radiation, and surgery.
Danielle Roman, PharmD, BCOP, FHOPA, explains how ASCO’s updated breast cancer surveillance guideline links follow-up intensity to recurrence risk and creates opportunities for pharmacist involvement.
FDA-approved capivasertib triplet improves rPFS in PTEN-deficient mCSPC; learn dosing, key drug interactions, and managing diarrhea, hyperglycemia, and rash.
Advertisement
Advertisement